COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

July 2, 2019
Proteomic Dataset Release of the CPTAC and CBTTC Collaborative Pediatric Brain Tumor Pilot Study

While it’s a common misconception that all tumors in the brain are the same, there are more than 120 subtypes of brain cancers with very diverse features and diagnosis.
June 27, 2019
Dr. Rodriguez Speaks at JSN, Fujita, and Nagoya University about the Power of Proteogenomics

Dr. Henry Rodriguez gave the keynote address at the 62nd Annual Meeting of the Japanese Society of Nephrology in Nagoya, Japan this week.  In line with the conference’s theme Open The Future, Dr.
June 13, 2019
The Magic of Proteogenomics Explained Series: CPTAC Proteogenomics Program

Since its first mention in the scientific literature in 2004 by Jaffe et al1, the term proteogenomics has been shrouded in mystery and thick technical language.  It is a complex idea, but one that is gaining traction as its value to improve our understanding of cancer development and potentially...
June 4, 2019
CPTAC Develops a New Technique (BASIL) to Enhance Phospho Sensitivity from a Small Population of Cells (feasibility on human pancreatic islets)

Phosphorylation is a key process in the regulation of protein activity and has long been appreciated as an essential mechanism for the control of cellular function - tells a protein where to go, what to bind to and even when to die.
May 28, 2019
CPTAC Releases Lung Adenocarcinoma (LUAD) Proteomic Dataset

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to release its newest comprehensive dataset - deep proteomic/phosphoproteomic data and imaging data of Lung Adenocarcinoma (LUAD) patient tumors.  The CPTAC Tumor Characterization Program uses proteogenomic analysis to systematically...
May 14, 2019
Congratulations to the Best Performers of the precisionFDA/NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Correction Big Data Challenge

Riding the wave of the future requires scientists to move away from silo-thinking to an inclusive and collaborative mind set. By leveraging the power of crowdsourcing, precisionFDA and NCI-CPTAC teamed up to launch the Multi-omics Enabled Sample Mislabeling Correction Big Data Challenge. Over 500...
April 25, 2019
CPTAC Researchers Analyze Colon Cancer Proteins and Genes to Uncover New Potential Treatments

Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.
April 8, 2019
Perspective on the clinical potential of mass spectrometry-based proteogenomics

Is DNA sequencing enough to recommend personalized treatments for cancer patients? In a article published in Nature Reviews Clinical Oncology, CPTAC investigators and colleagues from the Fred Hutch, Baylor College of Medicine, and University of Washington Medicine make the case for proteogenomics -...
April 2, 2019
CPTAC Genomic Data Now Available in the NCI Genomic Data Commons (GDC)

CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer.
March 14, 2019
Be Part of Tomorrow’s Next-Gen Big Data Scientists (BD-STEP Training Fellowship Announcement)

"Big data" is a term to describe data sets so large or complex that traditional data processing strategies are inadequate. As continued advancements in biomedical technologies generate an increasing amount of patient data, administration of patient-centered care will depend, in part, on the ability...

Pages

more

View all News and Announcements

NIH…Turning Discovery Into Health®